Efficacy and Safety of Plasma Exchange with 5% Albumin to Modify Cerebrospinal Fluid and Plasma Amyloid-β Concentrations and Cognition Outcomes in Alzheimer's Disease Patients: A Multicenter, Randomized, Controlled Clinical Trial
| Autor: | Joshua R. Shua-Haim, Isidre Ferrer, Pilar Ortiz, Montserrat Alegret, Joan Ramon Grifols, Thomas O. Obisesan, Fernando Anaya, Asunción Lafuente, Mar Buendía, Javier Olazarán, Lluís Tárraga, Oscar L. Lopez, Antonio Páez, Joan Muñoz, Laura Núñez, Mireia Torres, Mercè Boada, Isabel Hernández |
|---|---|
| Přispěvatelé: | Universitat de Barcelona |
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Male Phases of clinical research Sang Disease Neuropsychological Tests Gastroenterology plasma Aβ 0302 clinical medicine Cerebrospinal fluid Ús terapèutic Albúmines Verbal fluency test Aged 80 and over Plasma Exchange General Neuroscience Cognition General Medicine Middle Aged Magnetic Resonance Imaging Psychiatry and Mental health Clinical Psychology Boston Naming Test Blood Female CSF Aβ Pèptids Alzheimer’s disease Research Article medicine.medical_specialty Cognition disorders Tomography Scanners X-Ray Computed Trastorns de la cognició 03 medical and health sciences Alzheimer Disease Internal medicine Albumins medicine Humans Aged Psychiatric Status Rating Scales Amyloid beta-Peptides business.industry Albumin Líquid cefalorraquidi Therapeutic use Surgery Clinical trial 030104 developmental biology Geriatrics and Gerontology business Peptides Cognition Disorders 030217 neurology & neurosurgery Follow-Up Studies |
| Zdroj: | Journal of Alzheimer's Disease Recercat. Dipósit de la Recerca de Catalunya instname Dipòsit Digital de la UB Universidad de Barcelona Repositorio Institucional de la Consejería de Sanidad de la Comunidad de Madrid Consejería de Sanidad de la Comunidad de Madrid |
| ISSN: | 1875-8908 |
| Popis: | Background: studies conducted in animal models and humans suggest the presence of a dynamic equilibrium of amyloid-β (Aβ) peptide between cerebrospinal fluid (CSF) and plasma compartments. Objective: to determine whether plasma exchange (PE) with albumin replacement was able to modify Aβ concentrations in CSF and plasma as well as to improve cognition in patients with mild-moderate Alzheimer's disease (AD). Methods: in a multicenter, randomized, patient- and rater-blind, controlled, parallel-group, phase II study, 42 AD patients were assigned (1 : 1) to PE treatment or control (sham) groups. Treated patients received a maximum of 18 PE with 5% albumin (Albutein®, Grifols) with three different schedules: two PE/weekly (three weeks), one PE/weekly (six weeks), and one PE/bi- weekly (12 weeks), plus a six-month follow-up period. Plasma and CSF Aβ1-40 and Aβ1-42 levels, as well as cognitive, functional, and behavioral measures were determined. Results: CSF Aβ1-42 levels after the last PE compared to baseline were marginally higher in PE-treated group versus controls (adjusted means of variation: 75.3 versus -45.5 pg/mL; 95% CI: -19.8, 170.5 versus 135.1, 44.2; p = 0.072). Plasma Aβ1-42 levels were lower in the PE-treated group after each treatment period (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|